Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting
Affimed N.V. (Nasdaq: AFMD) has announced that their abstract focusing on AFM24 dose optimization has been accepted for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting in Chicago (April 25-30, 2025).
The presentation will detail dose optimization using exposure response analysis for AFM24, both as monotherapy and in combination with atezolizumab, in patients with advanced/metastatic non-small cell lung cancer. The poster presentation is scheduled for Tuesday, April 29, 2025, from 9:00 AM to 12:00 PM CDT in Poster Section 49.
Affimed N.V. (Nasdaq: AFMD) ha annunciato che il loro abstract incentrato sull'ottimizzazione della dose di AFM24 è stato accettato per una presentazione poster al prossimo American Association for Cancer Research (AACR) Annual Meeting a Chicago (25-30 aprile 2025).
La presentazione fornirà dettagli sull'ottimizzazione della dose utilizzando l'analisi della risposta all'esposizione per AFM24, sia come monoterapia che in combinazione con atezolizumab, in pazienti con carcinoma polmonare non a piccole cellule avanzato/metastatico. La presentazione del poster è programmata per martedì 29 aprile 2025, dalle 9:00 alle 12:00 CDT nella Sezione Poster 49.
Affimed N.V. (Nasdaq: AFMD) ha anunciado que su resumen enfocado en la optimización de la dosis de AFM24 ha sido aceptado para presentación en poster en la próxima Reunión Anual de la Asociación Americana para la Investigación del Cáncer (AACR) en Chicago (25-30 de abril de 2025).
La presentación detallará la optimización de la dosis utilizando análisis de respuesta a la exposición para AFM24, tanto como monoterapia como en combinación con atezolizumab, en pacientes con cáncer de pulmón no microcítico avanzado/metastásico. La presentación del poster está programada para el martes 29 de abril de 2025, de 9:00 AM a 12:00 PM CDT en la Sección de Posters 49.
Affimed N.V. (Nasdaq: AFMD)는 AFM24 용량 최적화에 대한 초록이 미국 암 연구 협회(AACR) 연례 회의에서 포스터 발표를 위해 수락되었다고 발표했습니다. 이 회의는 시카고에서 (2025년 4월 25일-30일) 열립니다.
발표에서는 AFM24의 용량 최적화를 단독 요법 및 아테졸리주맙과의 병용 요법으로 분석한 내용을 상세히 설명할 것입니다. 이 발표는 2025년 4월 29일 화요일, 오전 9시부터 오후 12시까지 CDT에서 포스터 섹션 49에서 진행될 예정입니다.
Affimed N.V. (Nasdaq: AFMD) a annoncé que leur résumé portant sur l'optimisation de la dose d'AFM24 a été accepté pour une présentation sous forme de poster lors de la prochaine Réunion Annuelle de l'Association Américaine pour la Recherche sur le Cancer (AACR) à Chicago (25-30 avril 2025).
La présentation détaillera l'optimisation de la dose en utilisant l'analyse de la réponse à l'exposition pour AFM24, tant en monothérapie qu'en combinaison avec l'atezolizumab, chez des patients atteints de cancer du poumon non à petites cellules avancé/métastatique. La présentation du poster est prévue pour le mardi 29 avril 2025, de 9h00 à 12h00 CDT dans la section des posters 49.
Affimed N.V. (Nasdaq: AFMD) hat bekannt gegeben, dass ihr Abstract zur Dosisoptimierung von AFM24 für eine Posterpräsentation auf dem kommenden Jahrestreffen der Amerikanischen Krebsgesellschaft (AACR) in Chicago (25.-30. April 2025) akzeptiert wurde.
Die Präsentation wird Details zur Dosisoptimierung durch Expositionsreaktionsanalyse für AFM24 liefern, sowohl als Monotherapie als auch in Kombination mit Atezolizumab, bei Patienten mit fortgeschrittenem/metastasiertem nicht-kleinzelligem Lungenkrebs. Die Posterpräsentation ist für Dienstag, den 29. April 2025, von 9:00 bis 12:00 Uhr CDT in Posterbereich 49 geplant.
- None.
- None.
MANNHEIM, Germany, March 25, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced an abstract on AFM24 dose optimization using exposure response analysis has been accepted for presentation as a poster at the Annual Meeting of the American Association for Cancer Research (AACR) taking place April 25-30, 2025 in Chicago, Illinois.
Details of the poster presentation are as follows:
Title: Dose-Optimization Using Exposure Response Analysis in AFM24 (in Monotherapy and with Atezolizumab) in Patients with Advanced/Metastatic Non-Small Cell Lung Cancer
Authors: Anthony El-Khoueiry, Omar Saavedra, Juanita Lopez, Hye Ryun Kim, Daniela Morales-Espinosa, Daniel Schütz, Andre Overesch, Andreas Harstrick, Kerstin Pietzko
Session Category and Title: Phase II Clinical Trials 1
Session Date and Time: Tuesday, April 29, 2025, 9:00 AM – 12:00 PM CDT
Location: Poster Section 49
Poster Board Number: 1
Published Abstract Number: CT161
The full abstract will be published online on April 25, 2025.
More details about the programs for the AACR Annual Meeting 2025 are available online at AACR Annual Meeting 2025 | Meetings | AACR.
About AFM24
AFM24 is a tetravalent, bispecific ICE® that activates the innate immune system by binding to CD16A on innate immune cells and epidermal growth factor receptors (EGFR), a protein widely expressed on solid tumors, to kill cancer cells. Generated by Affimed’s fit-for-purpose ROCK® platform, AFM24 represents a distinctive mechanism of action that uses EGFR as a docking site to engage innate immune cells for tumor cell killing through antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s innate cell engagers (ICE®) enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors. ICE® are generated on the Company’s proprietary ROCK® platform which predictably generates customized molecules that leverage the power of innate immune cells to destroy tumor cells. A number of ICE® molecules are in clinical development, being studied as mono- or combination therapy. Headquartered in Mannheim, Germany, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by the bold vision to stop cancer from ever derailing patients’ lives. For more about the Company’s people, pipeline and partners, please visit: www.affimed.com.
Investor Relations Contact
Alexander Fudukidis
Director, Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: +1 (917) 436-8102
Media Contact
Mary Beth Sandin
Vice President, Marketing and Communications
E-Mail: m.sandin@affimed.com
FAQ
What will Affimed (AFMD) present at AACR 2025 regarding AFM24?
When and where will AFMD's AFM24 poster be presented at AACR 2025?
What type of cancer patients are included in AFMD's AFM24 study?
What is the treatment combination being studied in AFMD's AFM24 research?
